← Back

Amoeba SA

Amoeba SA develops biological products and services for treating microbiological risk in the water, health, and plant protection sectors in France. Its water, surface, and chronic wound treatment technology uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky. The company also develops agricultural biocontrol technology to treat phytopathogenic microorganisms. Amoeba SA was incorporated in 2010 and is headquartered in Chassieu, France.

Country
Price · split & dividend adjusted
News & notes moving 0RAE.LSE
Synthetic Biology (non-pharma)

Syngenta and Amoéba Sign Exclusive European Biofungicide Deal

Syngenta Crop Protection AG and Amoéba have announced an exclusive supply and distribution agreement for a next-generation biocontrol fungicide, formulation AXP20, targeting cereal diseases across the European Union, the United Kingdom, Ukraine, and Switzerland. The binding long-term partnership, which converts a November 2025 memorandum of understanding, covers all cereals except corn and aims to control septoria tritici blotch and yellow rust, which together affect an estimated 9 to 12 million hectares annually. First market registrations are expected in the third quarter of 2028, with initial sales in core EU markets by the end of that year for spring 2029 use. The product, based on the lysate of the amoeba Willaertia magna C2c Maky, received EU approval in 2025 and is classified under FRAC Group BM02 with low resistance risk. Amoéba's managing director, Jean-Marc Petat, called the agreement a defining milestone, noting that Syngenta's screening selected AXP20 as the highest performing biofungicide among many biological solutions.
GlobeNewswire·10dRead more →